Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Divozilimab in Systemic Scleroderma
NCT05726630Phase 3Active, not recruiting
- Sponsor
- BIOCAD
- Start
- Dec 2022
- Primary completion
- Oct 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of Divozilimab in systemic sclerosis (SSc), sponsored by BIOCAD. Started Dec 2022; status: active, not recruiting.
02
Drugs
Divozilimab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT05726630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05726630.